Skip to main content
Clinical Trials/NCT03771352
NCT03771352
Completed
Not Applicable

A Prospective Multi-Center Clinical Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RxLAL) With the Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism

RxSight, Inc.2 sites in 2 countries55 target enrollmentJune 19, 2018
ConditionsCataract

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cataract
Sponsor
RxSight, Inc.
Enrollment
55
Locations
2
Primary Endpoint
Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

For patients undergoing cataract surgery, the purpose of this study is to evaluate a patient's far vision without glasses and quality of vision after implantation and UV treatment of the RxSight Light Adjustable Lens (RxLAL).Following completion of all light treatments, the patient's far vision without glasses and quality of vision will be assessed 6 months postoperatively.

Registry
clinicaltrials.gov
Start Date
June 19, 2018
End Date
July 1, 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Must sign a written Informed Consent form and be willing to undergo cataract surgery for the bilateral implantation of the RxLAL.
  • Greater than the age of 40 on the day the cataract surgery is performed.
  • Preoperative keratometric cylinder of \>=0.50 D and \<=4.00 D in both eyes.
  • Cataract causing reduction in best corrected distance visual acuity (BCDVA) to a level of 20/32 or worse with or without glare source in both eyes.
  • Willing and able to comply with the requirements for study specific procedures and visits.

Exclusion Criteria

  • Zonular laxity or dehiscence.
  • Age-related macular degeneration involving the presence of geographic atrophy or soft drusen.
  • Retinal degenerative disorder or macular disorder (other than mild macular degeneration) that is expected to cause future vision loss.
  • History of uveitis
  • Keratoconus or suspected of having keratoconus.
  • Previous corneal or intraocular surgery, except eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus.
  • Serious co-morbid conditions that in the judgement of the investigator makes inclusion in the study not in the best interest of the subject.
  • Subjects taking systemic medications that may increase sensitivity to UV light.
  • Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
  • History of ocular herpes simplex virus

Outcomes

Primary Outcomes

Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better

Time Frame: at 6 months postop

Percent of eyes with monocular uncorrected distance visual acuity of 20/20 or better

Study Sites (2)

Loading locations...

Similar Trials